Current and Future Trends in Myeloproliferative Neoplasms

An expert panel discusses recent updates in the treatment of myeloproliferative neoplasms from ASCO 2022.

EP. 1: Myeloproliferative Neoplasms: Essential Thrombocythemia

June 29th 2022

Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.

EP. 2: Managing Patients with Essential Thrombocythemia

June 29th 2022

Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.

EP. 3: Myeloproliferative Neoplasms: Polycythemia Vera

July 6th 2022

Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.

EP. 4: Treatment Options for Polycythemia Vera

July 6th 2022

An overview of the treatment options for patients with polycythemia vera.

EP. 5: PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera

July 13th 2022

Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.

EP. 6: Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms

July 13th 2022

A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.

EP. 7: Myeloproliferative Neoplasms: Myelofibrosis

July 22nd 2022

Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.

EP. 8: Risk Stratification for Myelofibrosis

July 22nd 2022

The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.

EP. 9: Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials

August 3rd 2022

A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.

EP. 10: New JAK Inhibitors in Myelofibrosis Treatment

August 3rd 2022

Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.

EP. 11: Efficacy and Safety of JAK Inhibitors for Myelofibrosis

August 11th 2022

Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.

EP. 12: Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022

August 11th 2022

Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.

EP. 13: Novel Agents Under Investigation for Myelofibrosis

August 11th 2022

The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.

EP. 14: Management of Accelerated Phase Myeloproliferative Neoplasms

August 11th 2022

Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.

EP. 15: Clinical Scenario: A 67-Year-Old with Myelofibrosis

August 18th 2022

Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.

EP. 16: Myelofibrosis Treatment Approaches after Disease Progression

August 18th 2022

A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.

EP. 17: Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis

August 24th 2022

Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.

EP. 18: The Future of Myeloproliferative Neoplasm Treatment

August 24th 2022

The panelists conclude their discussion by highlighting investigational agents to look forward to.